VIENNA, May 21, 2024
/PRNewswire/ -- YGION Biomedical GmbH, a company dedicated to
developing individualized neoantigen-based cancer vaccines, today
announced the completion of a Series A financing round of €15
million from an Austrian private trust. The proceeds will be used
to further develop YGION's unique YGNITETM technology
platform and advance the lead program YG-01 into preclinical and
clinical development.
Founded in 2022, YGION's high-profile team of experienced
biotech veterans and entrepreneurs are focused on developing
individualized "plug-and-play" cancer vaccines through a
proprietary suite of technologies to identify, produce and target
the delivery of relevant peptide neoepitopes resulting in safe,
exceptionally potent, and precise targeted activation of the
patient's immune system.
"We are on the cusp of a breakthrough in individualized cancer
treatments" said Dr. Wolfgang
Fischl, Chief Executive Officer of YGION. "This financing is
truly exciting for YGION as we see it as a strong validation of our
unique approach, and we are grateful for the support of our
investors enabling us to take a significant step towards clinical
validation of our technology. With the continued demonstration of
the efficacy of our approach, we are open to additional investors
and collaborators interested in our ground-breaking approach."
"We are confident that with our technology, we can realize the
promise of simple, safe and effective cancer vaccines" added Dr.
Geert Mudde, Chief Technology
Officer of YGION. "Our YGNITETM platform gives us the
unique ability to identify, select and synthesise relevant
neoantigens, and combined with our CARGONAUTTM
immune-modulating carrier induces a powerful cell-mediated tumor
specific response that targets and eliminates malignant cells with
unmatched safety."
YGION's lead program YG-01 is currently in preclinical
development.
About YGION Biomedical
YGION Biomedical is a private preclinical stage
biopharmaceutical company located in Vienna, Austria committed to realizing
individualized immunotherapies against cancer. YGION's YGNITE™
platform combines next generation sequencing, bioinformatics and
the proprietary CARGONAUT™ vaccine platform to deliver neoepitope
peptide vaccines tailored for each tumor and each patient.
For more information, visit www.ybion.bio
Contact
Sophie Zettl Ph.D.
Chief Business Officer, YGION Biomedical GmbH
sophie.zettl@ygion.bio
+43 660 573 1746
Logo -
https://mma.prnewswire.com/media/2415893/4712810/YGION_Biomedical_GmbH_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ygion-biomedical-announces-15-million-series-a-financing-to-develop-individualized-cancer-immunotherapies-302149012.html
SOURCE YGION Biomedical GmbH